# Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

> **NCT00645177** · PHASE2 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 10 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** ABT-869
- **DRUG:** paclitaxel
- **DRUG:** Placebo for ABT-869

## Key facts

- **NCT ID:** NCT00645177
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2013-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00645177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00645177, "Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00645177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*